We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection.
- Authors
Solms, Alexander; Lalezari, Shadan; Shah, Anita; Kenet, Gili
- Abstract
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection BAY 81-8973 (Kovaltry, Bayer, Berkeley, CA, USA) is an unmodified, full-length, recombinant factor VIII (rFVIII). Using the developed popPK model, and based on the study patients, half-life and predicted trough levels of BAY 81-8973 vs rFVIII-FS administered twice-weekly or three-times-weekly at steady state were estimated for different doses. Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate®) and BAY 81-8973 (Kovaltry®) in patients with severe or moderate haemophilia A in prophylaxis.
- Subjects
PHARMACOKINETICS; BLOOD coagulation factor VIII; EMPLOYEE ownership
- Publication
Haemophilia, 2020, Vol 26, Issue 3, pe145
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.13973